Trial reportBMC pulmonary medicine2017
Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
Trial report in BMC pulmonary medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.Advances in respiratory medicine · 2022Guideline
- Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Respiratory oscillometry identifies disease progression in interstitial lung disease.BMJ open respiratory research · 2026Observational
- Efficacy of antifibrotic treatment for ANCA-positive fibrosing interstitial lung disease: a retrospective case‒control study.BMC pulmonary medicine · 2026Article
- Role of antifibrotics in progressive pulmonary fibrosis associated to autoimmune diseases: multicenter study from NEREA registry.Respiratory research · 2025Article
- Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Hypersensitivity Pneumonitis.Tuberculosis and respiratory diseases · 2025Article
- Outcomes and predictors of progression in progressive pulmonary fibrosis.Annals of medicine · 2024Article
- Acute exacerbation of progressive pulmonary fibrosis: incidence and outcomes.Respiratory research · 2024Article
- Value of CT quantification in progressive fibrosing interstitial lung disease: a deep learning approach.European radiology · 2024Article
- Progressive pulmonary fibrosis: a need for real world data to solve real world clinical problems.BMJ medicine · 2024Article
- Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease.Scientific reports · 2023Article
- Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort.Journal of thoracic disease · 2023Article
- Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.BMC pulmonary medicine · 2023Article
- Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases.Frontiers in medicine · 2023Article
- Lung Damage in Rheumatoid Arthritis-A Retrospective Study.International journal of molecular sciences · 2022Article
- Review
- Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.Biomedicines · 2022Review
- Lung function trajectory in progressive fibrosing interstitial lung disease.The European respiratory journal · 2022Article
- Irreversibility of Pulmonary Fibrosis.Aging and disease · 2022Review
- Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort.African journal of thoracic and critical care medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive fibrotic lung diseases, in which conventional anti-inflammatory therapy is not sufficiently effective and antifibrotic therapies may offer a novel treatment option. METHODS/
designWe designed a study protocol for inclusion of patients with progressive fibrotic lung disease despite conventional anti-inflammatory therapy (EudraCT 2014-000861-32). The study population comprises patients with collagen-vascular disease-associated lung fibrosis (CVD-LF), fibrotic non-specific interstitial pneumonia (fNSIP), chronic hypersensitivity pneumonitis (cHP), and asbestos-related lung fibrosis (ALF). Disease progression needs to be proven by slope calculation of at least three Forced Vital Capacity (FVC) values obtained within 6-24 months prior to inclusion, documenting an annualized decline in percent predicted FVC of 5% (absolute) or more despite appropriate conventional therapy. Absolute change in percent predicted FVC from baseline - analyzed using a rank analysis of covariance (ANCOVA) model - will serve as efficacy-related primary study endpoint. DISCUSSION: There is an urgent unmet clinical need for effective therapies for patients with a progressive fibrotic lung disease other than IPF. The current study protocol is unique with respect to selecting patients with different disease entities of lung fibrosis which have, however, essential pathophysiological characteristics in common. Moreover, by selecting patients with evidence of disease progression despite conventional therapy, the protocol ensures that a cohort of interstitial lung disease (ILD) patients with a high unmet medical need is targeted and it may allow a sufficiently high event rate for evaluation of treatment responses.
trial registrationDRKS00009822 (registration date: January 13th 2016).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.